Glenmark Generics Receives Approval For Hydrocortisone Butyrate Cream USP …RTT NewsGlenmark Pharmaceuticals Ltd. said its US subsidiary Glenmark Generics Inc. had received the approval from US FDA for Hydrocortisone Butyrate Cream USP, 0.1 percent, a…
Everolimus Slows Disease Progression In Advanced Papillary Kidney Cancer …Science 2.0The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it …
|
Everolimus Slows Disease Progression in Advanced Kidney Cancer Patients
Science Daily (press release) Sep. 27, 2013 — The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease … |
Everolimus slows disease progression in advanced papillary kidney cancer …Medical XpressThe first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that …
Everolimus slows disease progression in advanced papillary kidney cancer …EurekAlert (press release)The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has…
|
Everolimus effective in women with early failure of adjuvant therapy
The Oncology Report SAN FRANCISCO – In patients who had hormone receptor–positive, HER2-negative advanced breast cancer, everolimus plus exemestane was just as effective among women who had a recurrence during or within a year of adjuvant therapy. The results … |
|
Everolimus effective in women with early failure of adjuvant therapy
Ob.Gyn. News Digital Network SAN FRANCISCO – In patients who had hormone receptor–positive, HER2-negative advanced breast cancer, everolimus plus exemestane was just as effective among women who had a recurrence during or within a year of adjuvant therapy. The results … |
|
Genetic alterations may predict everolimus efficacy
The Oncology Report SAN FRANCISCO – Among postmenopausal women with advanced hormone receptor–positive breast cancer, everolimus appeared to be more effective in the patients with one or no alterations in four key genes. In a secondary analysis of data from the … |
Health and Beauty News (blog)Inhaled corticosteroids can lead to pneumoniaHealth and Beauty News (blog)As according to a research conducted by University of Alberta it was found out that doctors should be very cautious while prescribing inhaled cortico…
First-line everolimus plus exemestane prolonged PFS in advanced breast cancerHealioThe addition of the mTOR inhibitor everolimus to first-line exemestane therapy extended PFS compared with exemestane alone in patients with hormone receptor-positive adv…